Today Pfizer-BioNTech released results from the first phase 2/3 trial of its COVID-19 mRNA vaccine on children ages 5 to 11, and said the vaccine was both safe and produced neutralizing antibodies to the novel coronavirus.The trail considered a two-dose regimen of 10 micrograms (µg) administered 21 days apart, a smaller dose than the 30 µg dose used for people 12 and older, Pfizer said in a press release.
The study included 2,268 participants. The trial is also studying that dose in children ages 6 months to 11 years."Over the past nine months, hundreds of millions of people ages 12 and older from around the world have received our COVID-19 vaccine.